The legality of fixing genetic disorders in embryos

To further public understanding of regenerative medicine, EuroStemCell has published lay summaries for all articles from the latest Regenerative Medicine special focus issue.

Go to the profile of Regenerative Medicine
Dec 05, 2017
0
0
Upvote 0 Comment

EuroStemCell have launched a digital platform to accompany the publication of the Regenerative Medicine two-part Special Focus Issue entitled “Regenerative Medicine in Society: Interdisciplinary Perspectives”. The platform presents lay summaries of each article in the issue which are freely available to all in order to engage and educate non-experts on the key issues surrounding regenerative medicine.

You can now read the lay summary for the article entitled, “Legal issues regarding gene editing at the beginning of life: an EU perspective” from Iñigo De Miguel Beriain [1].

DNA editing methods have advanced to the point that they could be used on human embryos to correct gene mutations that cause numerous diseases at the earliest stages of life. While there are ethical issues to address about such technology, the legality of this is not often discussed. Current laws and regulations are examined to understand the current legality of editing the DNA of embryos for medical purposes for Europe and its member states.

What questions & challenges are raised? What insight and direction does this give for research policies? To find out, read the full lay summary on the EuroStemCell website here: https://www.eurostemcell.org/regenerative-medicine-society/legality-fixing-genetic-disorders-embryos

The full original article can be accessed here: https://www.futuremedicine.com/doi/10.2217/rme-2017-0033

 

References

[1] De Miguel Beriain I. Ethical and legal issues regarding gene editing at the beginning of life: an EU perspective. Regen. Med. 12(6), 669–679 (2017).

Go to the profile of Regenerative Medicine

Regenerative Medicine

Journal, Future Science Group

Regenerative Medicine is an award-winning peer-reviewed journal, in print and web formats. The journal provides a forum to address the important challenges and advances in stem cell research and regenerative medicine, delivering this essential information in concise, clear and attractive article formats. Among other indexing services Regenerative Medicine is listed by MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, Science Citation Index Expanded™ (SciSearch®), Emcare, Biological Abstracts, BIOSIS Previews, Biotechnology Citation Index®, Journal Citation Reports/Science Edition®, Scopus® with an Impact Factor of 2.786 (2014). Each issue contains expertly drafted Reviews, Original Research articles, Perspectives, Editorials, topical insight from international leaders in their field, and additional added-value content. The Senior Editor of the journal is Professor Chris Mason, University College London. You can find out more about Regenerative Medicine at our website (www.future-science-group.com/journalprofile/regenerative-medicine/), where you can find the aims and scope of the journal and details of our international editorial board.

No comments yet.